S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Otonomy Stock Forecast, Price & News

-0.50 (-8.77 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $5.20
50-Day Range
MA: $5.57
52-Week Range
Now: $5.20
Volume1.18 million shs
Average Volume550,409 shs
Market Capitalization$250.79 million
P/E RatioN/A
Dividend YieldN/A
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Otonomy logo


Overall MarketRank

1.51 out of 5 stars

Medical Sector

350th out of 1,556 stocks

Pharmaceutical Preparations Industry

182nd out of 638 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OTIC



Sales & Book Value

Annual Sales$600,000.00
Book Value$1.31 per share


Net Income$-44,670,000.00
Net Margins-11,386.86%


Market Cap$250.79 million
Next Earnings Date2/25/2021 (Estimated)
-0.50 (-8.77 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

How has Otonomy's stock been impacted by Coronavirus?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OTIC stock has increased by 98.5% and is now trading at $5.20.
View which stocks have been most impacted by COVID-19

Is Otonomy a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Otonomy?

Wall Street analysts have given Otonomy a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Otonomy wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Otonomy

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) posted its earnings results on Wednesday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.11 million. Otonomy had a negative return on equity of 125.30% and a negative net margin of 11,386.86%.
View Otonomy's earnings history

What price target have analysts set for OTIC?

4 brokerages have issued twelve-month price objectives for Otonomy's shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Otonomy's share price to reach $10.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Otonomy
or view Wall Street analyst' top-rated stocks.

Are investors shorting Otonomy?

Otonomy saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,110,000 shares, an increase of 35.8% from the December 15th total of 817,100 shares. Based on an average daily trading volume, of 366,300 shares, the days-to-cover ratio is presently 3.0 days.
View Otonomy's Short Interest

Who are some of Otonomy's key competitors?

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Who are Otonomy's key executives?

Otonomy's management team includes the following people:
  • Dr. Jay B. Lichter, Co-Founder & Independent Chairman (Age 59, Pay $60k)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 61, Pay $875.12k)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 59, Pay $554.52k)
  • Mr. Robert Michael Savel II, Chief Technical Officer (Age 53, Pay $498.26k)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
  • Dr. Rick Adam Friedman M.D., Ph.D., Co-Founder and Member of the Advisory Panel
  • Ms. Julie D. Burgess, VP of Fin. & Admin.
  • Ms. Carla da Luz Boren, Gen. Counsel & Chief HR Officer

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $5.20.

How big of a company is Otonomy?

Otonomy has a market capitalization of $250.79 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.